Within the ELN2022 favorable risk group, patients with core-binding factor (CBF) AML tended to have longer EFS than patients with in-frame CEBPA bZIP or NPM1 mutations (Fig. 3A), but did not differ in CIR or OS (Supplementary Fig. S6A, B). The gene discussed is CEBPA; the disease is acute myeloid leukemia.